PARSIPPANY, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference at 10:30 AM PT (1:30 PM EST) on Wednesday, January 15, 2025. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event. About PaciraPacira delivers innovative, non-opioid pain therapies to ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

Pacira BioSciences (PCRX) announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel (bupivacaine liposome injectable suspension), ensuring protection against generics in the market through 2044. The ‘940 patent is the first from a new family of patents related to Exparel produced by Pacira’s enhanced large-scale manufacturing process in San Diego, which received FDA approval in February 2024.Exparel is Pacira’s flagship pain-manage ...

-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced the receipt of U.S. Patent No. 12,156,940 (the ‘940 patent) from the U.S. Patent and Trademark Office (the U.S. PTO). The ‘940 patent, entitled “Manufacturing of Bupivacaine Multivesicular Liposomes” pr ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Pacira BioSciences, Inc. (NASDAQ: PCRX ) stock currently trades at a value of $18, although in 2015 it traded at $115 per share, and in March 2022, >$75 per share. Since th ...

Pacira BioSciences, Inc. (PCRX) reported third-quarter 2024 adjusted earnings of 79 cents per share, which beat the Zacks Consensus Estimate of 72 cents. The company had reported adjusted earnings of 72 cents per share in the year-ago quarter.Total revenues amounted to $168.6 million, which increased 3% year over year but missed the Zacks Consensus Estimate of $169 million.PCRX’s Q3 Results in DetailPacira’s top line comprises product sales and royalty revenues. The company recognizes product revenues from ...

Pacira Biosciences Inc. (NASDAQ:PCRX) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Shawn Cross - Chief Financial Officer Kristen Williams - Chief Administrative Officer Lauren Riker - Senior Vice President Finance Jonathan Slonin - Chief Medical Officer Conference Call Participants Oren Livnat - H.C. Wainwright David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Good day, an ...

Pacira (PCRX) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.72%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.73 per share when it actually produced earnings of $0.89, delivering a surprise of 21.92%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35060 PACIRA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 51-0619477 (State or Other J ...